Imject Blue Carrier Protein is a highly soluble, mollusk-derived hemocyanin that enable simple preparation of effective immunogens with amine- or carboxyl-peptide antigens.
Features of Imject Blue Carrier Protein:
• High-yield conjugation—
each molecule of CCH contains hundreds of primary amines available for coupling haptens via EDC or NHS ester crosslinkers
• Validated quality—
the immunogenic carrier protein is specially purified to ensure uniform chemical structure and solubility for consistent performance
• Superior solubility—
increased solubility compared to KLH allows Blue Carrier Protein to be used in a broader range of conjugation protocols to accommodate unusual or poorly soluble haptens
• Highly immunogenic—
provides essentially the same level of immunogenicity and phylogenetic distance as keyhole limpet hemocyanin (KLH)
Blue Carrier Protein is a purified preparation of Concholepas concholepas
hemocyanin (CCH) that confers high immunogenicity to conjugated antigens for injection and immunization in antibody production procedures. The large protein exhibits most of the same immunogenic properties as the popular carrier protein, keyhole limpet hemocyanin (KLH). However, its signficantly better solubility provides greater flexibility in immunogen preparation protocols by allowing a broader range of buffer and pH conditions for coupling peptides, proteins and other haptens using classical crosslinkers such as glutaraldehyde, Sulfo-SMCC and EDC. The accompanying Thermo Scientific Imject EDC Blue Carrier Spin Kit provides for easy immunogen preparation.Properties of Blue Carrier Protein:
• Alternative names: Concholepas concholepas
• Molecular weight:
Whole molecule: ∼ 8,000,000; Subunits: ∼ 400,000 and ∼ 350,000
maxima 280nm, 350nm and 558nm
• Extinction Coefficient (A 1 mg/mL solution):
1.4 @ 280nm; 0.35 @ 346nm
• A280/A350 Ratio:
• Copper/protein ratio:
∼ 16 Cu2+
per protein molecule
• Isoelectric point:
Soluble in aqueous buffers: pH 7.0-8.0
Stable in aqueous buffers: ∼ pH 7.2 without Ca2+
Carrier proteins are large, complex molecules capable of stimulating an immune response upon injection. Successful production of antibodies specific to small antigens (i.e., peptides or drug compounds) requires that these haptens be covalently conjugated to a larger, more complex molecule (usually a protein) to make them immunogenic. Carrier proteins are chosen based on immunogenicity, solubility, and whether an adequate level of hapten-carrier conjugation can be achieved.
Blue Carrier Protein is specially purified hemocyanin from the mollusk Concholepas concholepas
. The CCH protein is composed of two very large polypeptide subunits (404/351 kDa) that form an extremely stable heterodidecameric structure even in the absence of divalent cations. (By contrast, KLH has a less stable and soluble homodidecameric structure). The complex molecular arrangement of CCH subunits contains diverse repeated antigenic structures that elicit a strong immune reaction mediated by T and B lymphocytes.
Because of their large size and molecular complexity, KLH and CCH hemocyanins are carrier proteins of choice for use as immunogens to produce antibodies against haptens and peptides. Moreover, studies suggest that the strong DTH immune response elicited by hemocyanins in animals and in humans has beneficial therapeutic effects in certain types of cancer. New developments in the immunotherapy of cancer have taken advantage of the unique immunogenic properties of hemocyanins in the development of novel conjugate vaccines for treatment of emerging diseases.
The carbodiimide crosslinker EDC conjugates carboxyl-containing haptens
(e.g., C-terminus of peptide antigens) to BSA carrier protein. This method of immunogen preparation is ideal for peptide antigens with few or no aspartic and glutamic acid residues (carboxylates) and lysine residues (primary amines) within the central portion of the primary sequence. Because peptides contain both carboxylate and amines, EDC conjugation results in their becoming variously polymerized and randomly oriented in their linkage to the carrier protein. Typically, this results in a high level of antigen loading on the carrier protein as well as presentation in all possible orientations for antibody production. However, important (desired) epitopes within the antigen peptide sequence may be blocked by EDC-mediated conjugation if those regions contain primary amines (lysine residues) or carboxylates (aspartic and glutamic acid residues). In these cases, either use a homobifunctional amine-reactive crosslinker with the purified Blue Carrier in phosphate buffer or synthesize the peptide with a unique terminal cysteine and use a kit with Malemide-Activated Blue Carrier
to prepare the carrier protein conjugate.More Product Data
• Carrier protein activation and conjugation data for immunogen preparationRelated ProductsImject™ Blue Carrier™ Protein (in sterile PBS)Imject™ EDC Blue Carrier™ Protein Spin Kit
For Research Use Only. Not for use in diagnostic procedures.